<DOC>
	<DOCNO>NCT01575769</DOCNO>
	<brief_summary>This long-term , interventional , open-label extension study evaluate safety efficacy RoActemra/Actemra ( tocilizumab ) patient Poland Russia polyarticular-course juvenile idiopathic arthritis complete WA19977 study . Patients receive RoActemra/Actemra 8 mg/kg every 4 week . The anticipated time study treatment 104 week .</brief_summary>
	<brief_title>An Extension Study WA19977 Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>Patients complete 104 week study WA19977 least JIA ACR30 clinical response RoActemra/Actemra serious adverse event adverse event Written inform consent obtain patient patient 18 year age old , age 18 year parent legal guardian Patient benefit RoActemra/Actemra therapy study WA19977 Treatment investigational drug since last administration study drug core study WA19977 Patients develop autoimmune rheumatic disease permit JIA subset Any significant medical surgical condition would jeopardize patient 's safety Current serious uncontrolled concomitant disease infection</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>